Share Buyback In H. Lundbeck A/S

Valby, Denmark, May 3, 2008 - (ABN Newswire) - Acting on its authorization to acquire up to 10% of its shares, Lundbeck's Supervisory Board has resolved to initiate a share buyback program. Under the program Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005. The buyback program is expected to be completed by the end of 2008.

  During any one single trading day a maximum of 25% of the average daily trading volume of Lundbeck shares on OMX Nordic Exchange Copenhagen, calculated over 20 days prior to each trading date, will be bought back, as the share buyback program is implemented in accordance with the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003.   At least once every seven trading days, Lundbeck will issue an announcement in respect of the transactions made under the program.   The following transactions have been made under the program:  

  No. of shares Average Transaction value purchase price (DKK) (DKK) Accumulated, last 29,550,136 133.7885 3,953,468,867 announcement 23 April 2008 67,200 111.4657 7,490,495.38 24 April 2008 67,000 114.0570 7,641,819.00 25 April 2008 -- -- -- 28 April 2008 16,787 117.0585 1,965,061.04 29 April 2008 -- -- -- 30 April 2008 50,200 117.8089 5,914,005.53 1 May 2008 90,200 118.5593 10,670,332.50 Accumulated under the 29,841,323 133.6117 3,987,150,581 program

    Following the above buyback it is hereby announced that Lundbeck owns a total of 10,684,536 own shares at a nominal value of DKK 5, equal to 5.15% of the total number of 207,279,631 shares.   Lundbeck contacts  

Investors: Media:     Jacob Tolstrup Jens Højbjerg Director Media Relations Manager +45 36 43 30 79 +45 36 43 28 33     Palle Holm Olesen   Head of Investor Relations   +45 36 43 24 26  

  Stock Exchange Release No 339 - 2 May 2008   About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.5 billion or USD 2.0 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com



LINK: http://hugin.info/130085/R/1215655/253732.pdf

Copyright © Hugin AS 2008. All rights reserved.

H. Lundbeck

http://www.lundbeck.com
ISIN: DK0010287234

Stock Identifier: XCSE.LUN